CelSci (CVM)
(Real Time Quote from BATS)
$1.05 USD
-0.03 (-2.78%)
Updated Sep 25, 2024 12:06 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Cel-Sci Corporation [CVM]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Fireside Chat Shows LEAPS Could Be a Potential Leap Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $18 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Multikine Phase 3 nearing 3-Year Milestone
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Termination of Coverage -Analyst(s) Departure
Provider: DAWSON JAMES SECURITIES, INC.
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
FDA Puts Phase III Multikine? Trial on Clinical Hold
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: Cel-Sci Corporation
Industry: Medical - Biomedical and Genetics
Suspended research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.
Provider: DAWSON JAMES SECURITIES, INC.